Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
In a January 2018 direct final rule, FDA presented a risk-based inspection frequency for establishments of biological drug prod- ucts and the removal of requirements regarding the inspectors’ duties. FDA believed the proposals were “noncontroversial” and anticipated “no significant adverse comments.” However, due to “significant adverse comment,” the rule has been withdrawn.
[/membership]
